ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Diagnostics

FDA approves Lilly’s Alzheimer’s diagnostic

by Michael McCoy
June 5, 2020 | APPEARED IN VOLUME 98, ISSUE 22

 

09822-buscon16-flor.jpg

The US Food and Drug Administration has approved Eli Lilly and Company’s Tauvid (18F-flortaucipir), the first diagnostic agent to image tau neurofibrillary tangles in the brain. The tangles are associated with Alzheimer’s disease. In 2012 the FDA approved a Lilly imaging agent, Amyvid (18F-florbetapir), that detects amyloid plaques associated with the disease.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment